Linker ID	LIN0VZYER
Linker Name	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
Linker Type	Thiol-sensitive linker
Antibody-Linker Relation	Cleavable
Structure
	3D MOL			2D MOL
Formula	C13H14N2O4S2
Isosmiles	C1CC(=O)N(C1=O)OC(=O)CCCSSC2=CC=CC=N2
PubChem CID	11551591
InChI	InChI=1S/C13H14N2O4S2/c16-11-6-7-12(17)15(11)19-13(18)5-3-9-20-21-10-4-1-2-8-14-10/h1-2,4,8H,3,5-7,9H2
InChIKey	JSHOVKSMJRQOGY-UHFFFAOYSA-N
IUPAC Name	(2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate
Pharmaceutical Properties	Molecule Weight		326.4	Polar area		127
	Complexity		390	xlogp Value		1
	Heavy Count		21	Rot Bonds		8
	Hbond acc		7	Hbond Donor		0

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Objective Response Rate (ORR)	40.00%	Low CEACAM5 expression (CEACAM5+; 299,300 sites/cell)
Patients Enrolled	Patients with advanced/metastatic nonsquamous non-small cell lung cancer (NSQ NSCLC) with CEACAM5 intensity of 2+ in 1% of tumor cells by immunohistochemistry.
Administration Dosage	IV Q3W at 150 or 170 mg/m2.
Related Clinical Trial
NCT Number	NCT04524689	Clinical Status	Phase 2
Clinical Description	Open-label, phase 2 study of tusamitamab ravtansine (SAR408701) combined with pembrolizumab and tusamitamab ravtansine (SAR408701) combined with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5 positive expression advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC).
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Objective Response Rate (ORR)	20.30% (CEACAM5 High-expression) 7.10% (CEACAM5 Moderate-expression) 41.70% (high cCEA) 8.10% (Low cCEA)	Moderate CEACAM5 expression (CEACAM5++; 1,615,700 sites/cell)
Patients Enrolled	Enrolled 2 cohorts of patients with IHC CEACAM5 membrane expression at 2+ intensity: in 50% of tumor cells (high expressors, HEs, n = 64); and in 1% to <50% of tumor cells (moderate expressors, MEs, n = 28).
Administration Dosage	100 mg/m2 IV every 2 weeks.
Related Clinical Trial
NCT Number	NCT02187848	Clinical Status	Phase 1
Clinical Description	A first-in-human study for the evaluation of the safety, pharmacokinetics and antitumor activity of SAR408701 in patients with advanced solid tumors.
Primary Endpoint	The primary endpoint was the incidence of DLTs occurring during the first two cycles (4 weeks) of study drug administration. DLTs (reversible grade 3 microcystic keratopathy) occurred in three of eight patients treated with tusamitamab ravtansine 12.00 mg/m2 and in two of three patients treated with 15.00 mg/m2. The maximum tolerated dose was identified as 10.00 mg/m2.    Click to Show/Hide
Other Endpoint	Three patients (9.68%) had objective responses [all confirmed partial responses (PRs) with durations of 2.60, 6.10, and 4.00 months]; 11 patients (35.48%) had stable disease, and 13 patients (41.94%) had progressive disease. Objective responses were achieved in two of six patients (33.33%) at a DL of 10.0 mg/m2, and in one of nine patients (11.11%) at 12.0 mg/m2 with maximum reduction in RECIST target lesions of 32.30%-51.20%.    Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC					[3]
Related Clinical Trial
NCT Number	NCT05703555	Clinical Status	Phase 2
Clinical Description	Intrusion: unraveling the intratumoral PK/PD relation for SAR408701.
Experiment 4 Reporting the Activity Date of This ADC					[4]
Related Clinical Trial
NCT Number	NCT05245071	Clinical Status	Phase 2
Clinical Description	Open-label, phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (nsq NSCLC) participants with negative or moderate CEACAM5 expression tumors and high circulating CEA.
Experiment 5 Reporting the Activity Date of This ADC					[5]
Related Clinical Trial
NCT Number	NCT05071053	Clinical Status	Phase 2
Clinical Description	Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CEACAM5-positive tumors.
Experiment 6 Reporting the Activity Date of This ADC					[6]
Related Clinical Trial
NCT Number	NCT04659603	Clinical Status	Phase 2
Clinical Description	Open-label, multi-cohort, phase 2 trial, evaluating the efficacy and safety of tusamitamab ravtansine (SAR408701) monotherapy and in combination in patients with CEACAM5-positive advanced solid tumors.
Experiment 7 Reporting the Activity Date of This ADC					[7]
Related Clinical Trial
NCT Number	NCT05429762	Clinical Status	Phase 1
Clinical Description	Open-label study evaluating the effect of tusamitamab ravtansine on the QTC interval in participants with metastatic solid tumors.
Experiment 8 Reporting the Activity Date of This ADC					[8]
Related Clinical Trial
NCT Number	NCT04154956	Clinical Status	Phase 1
Clinical Description	Randomized, open-label, phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors.
Experiment 9 Reporting the Activity Date of This ADC					[9]
Related Clinical Trial
NCT Number	NCT03324113	Clinical Status	Phase 1
Clinical Description	A phase 1 study to evaluate safety and pharmacokinetics of SAR408701 administered intravenously as monotherapy in japanese patients with advanced malignant solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	0.00% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 2 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	6.40% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 3 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	27.10% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 4 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	32.90% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 5 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	41.50% (Day 17)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 6 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	55.00% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 7 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	57.20% (Day 17)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 8 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	60.30% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 9 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	63.90% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 10 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	66.20% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 11 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	69.70% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 12 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	69.80% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 13 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	70.20% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 14 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	71.80% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 15 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	76.50% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 16 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	84.70% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 17 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90.20% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 18 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90.30% (Day 28)	Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model	Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 19 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	91.40% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 20 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.40% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 21 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.80% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 22 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.80% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 23 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.30% (Day 17)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model	Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 24 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.50% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 25 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	97.00% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 26 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.40% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 27 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.90% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 28 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00% (Day 28)	High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description	Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model	Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)

Experiment 1 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.20±0.04 nM	Low CEACAM5 expression (CEACAM5+; 498,900 sites/cell)
Method Description	The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313
Experiment 2 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38±0.07 nM
Method Description	The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313
Experiment 3 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.08±0.17 nM
Method Description	The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model	Gastric adenocarcinoma	MKN45 cells		CVCL_0434

Experiment 1 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Partial Response (PR)	9.00%
Patients Enrolled	Eastern Cooperative Oncology Group (ECOG) 0, 1, metastatic or locally advanced unresectable solid tumors with progressive disease (PD) after standard treatment or known intolerance to available treatment, based on the predicted prevalence of CD166 expression, were breast cancer, castration-resistant prostate cancer, nonsmall cell lung cancer (NSCLC), epithelial ovarian cancer, head and neck squamous cell cancer (HNSCC), cholangiocarcinoma, and endometrial carcinoma.    Click to Show/Hide
Administration Dosage	Scalating doses every 3 weeks (0.25-10 mg/kg) or every 2 weeks (4-6 mg/kg), IV.
Related Clinical Trial
NCT Number	NCT03149549	Clinical Status	Phase 1/2
Clinical Description	A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors (PROCLAIM-CX-2009).
Primary Endpoint	Median number of prior therapies was 5. On the basis of tolerability, the RP2D was 7 mg/kg every 3 weeks. Tumor regressions were observed at doses 4 mg/kg.

Experiment 1 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Objective Response Rate (ORR)	9.60%	Moderate MSLN expresion (MSLN++; 135,000-480,000 CD48 molecules/cell)
Patients Enrolled	Unresectable locally advanced or metastatic malignant pleural mesothelioma, an Eastern Cooperative Oncology Group performance status of 0-1, and who had progressed on first-line platinum-pemetrexed chemotherapy with or without bevacizumab.
Administration Dosage	Anetumab ravtansine (6.50 mg/kg once every 3 weeks) via intravenous infusion for 1 h on day 1 of each 21-day cycle, or vinorelbine (30 mg/m2 once every week) via intravenous injection for 610 min.
Related Clinical Trial
NCT Number	NCT02610140	Clinical Status	Phase 2
Clinical Description	A randomized, open-label, active-controlled, phase 2 study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy.
Primary Endpoint	For 6.50 mg/kg anetumab ravtansine,median progression-free survival 4.30 months [95% CI 41.00-52.00].
Experiment 2 Reporting the Activity Date of This ADC					[13]
Efficacy Data	Objective Response Rate (ORR)	27.70% (all treated patients) 42.10% (In high mesothelin expression patients(N=19) who received 3 prior lines of systemic therapy)	High MSLN expresion (MSLN+++; 19,998 MSLN molecules/cell)
Patients Enrolled	Predominantly epithelial (>50% of tumor component) platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Administration Dosage	Anetumab ravtansine (5.50 or 6.50 mg/kg) and pegylated liposomal doxorubicin (30 mg/m2) were administered intravenously every 3 weeks to 65 patients with platinum-resistant epithelial ovarian cancer.
Related Clinical Trial
NCT Number	NCT02751918	Clinical Status	Phase 1b
Clinical Description	An open-label phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and maximum tolerated dose of anetumab ravtansine in combination with pegylated liposomal doxorubicin 30 mg/m<sup>2</sup> given every 3 weeks in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer.    Click to Show/Hide
Primary Endpoint	The maximum tolerated dose of anetumab ravtansine in combination was 6.50 mg/kg administered every 3 weeks. No patient experienced a dose-limiting toxicity at either dose in the dose escalation cohort.
Other Endpoint	In all treated patients, ORR=27.70% (95% CI 17.30% to 40.20%), including one complete (1.50%) and 17 partial responses (26.20%). Mdor=7.60 months (95% CI 3.30 to 10.20), mPFS=5.0 months (95% CI 3.20 to 6.00). In high mesothelin expression patients (N=19), who received 3 prior lines of systemic therapy, ORR=42.10% (95% CI 20.30% to 66.50%), mDOR=8.30 months (95% CI 4.10 to 12.00), mFPS=8.50 months (95% CI 4.00 to 11.40).    Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Objective Response Rate (ORR)	31.00% (6.5 mg/kg, Mesothelioma)	Moderate MSLN expresion (MSLN++; 1105 MSLN molecules/cell)
Patients Enrolled	Advanced, metastatic, or recurrent solid tumors refractory to standard therapy.
Administration Dosage	0.15, 0.30, 0.60, 1.20, 2.40, 3.60, 4.50, 5.50, 6.50, and 7.50 mg/kg once every 3 weeks.
Related Clinical Trial
NCT Number	NCT01439152	Clinical Status	Phase 1
Clinical Description	An open label phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY94-9343 in subjects with advanced solid tumors.
Experiment 4 Reporting the Activity Date of This ADC					[16]
Related Clinical Trial
NCT Number	NCT03926143	Clinical Status	Phase 2
Clinical Description	An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous bayer-sponsored studies.
Experiment 5 Reporting the Activity Date of This ADC					[17]
Related Clinical Trial
NCT Number	NCT03587311	Clinical Status	Phase 2
Clinical Description	A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer.
Experiment 6 Reporting the Activity Date of This ADC					[18]
Related Clinical Trial
NCT Number	NCT03023722	Clinical Status	Phase 2
Clinical Description	An open-label, phase 2 study of intravenous anetumab ravtansine (BAY 94-9343), an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer.
Experiment 7 Reporting the Activity Date of This ADC					[19]
Related Clinical Trial
NCT Number	NCT02839681	Clinical Status	Phase 2
Clinical Description	Phase 2 trial with safety run-in of the anti-mesothelin antibody drug conjugate anetumab ravtansine for mesothelin expressing lung adenocarcinoma.
Experiment 8 Reporting the Activity Date of This ADC					[20]
Related Clinical Trial
NCT Number	NCT02610140	Clinical Status	Phase 2
Clinical Description	A randomized, open-label, active-controlled, phase 2 study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy.
Experiment 9 Reporting the Activity Date of This ADC					[21]
Related Clinical Trial
NCT Number	NCT03126630	Clinical Status	Phase 1/2
Clinical Description	Phase 1 safety run-in and phase 2 randomized clinical trial of anetumab ravtansine and pembrolizumab (MK-3475) compared to pembrolizumab alone for mesothelin-positive malignant pleural mesothelioma.
Experiment 10 Reporting the Activity Date of This ADC					[22]
Related Clinical Trial
NCT Number	NCT03816358	Clinical Status	Phase 1
Clinical Description	A phase 1 study of anetumab ravtansine in combination with either anti-PD-1 antibody, or anti-CTLA4 and anti-PD-1 antibodies or anti-PD-1 antibody and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma.
Experiment 11 Reporting the Activity Date of This ADC					[23]
Related Clinical Trial
NCT Number	NCT03455556	Clinical Status	Phase 1
Clinical Description	Phase 1/2 study of the human anti-mesothelin antibody drug conjugate anetumab ravtansine (AR), combined with the PD-L1 inhibitor atezolizumab in non-small cell lung cancer.
Experiment 12 Reporting the Activity Date of This ADC					[24]
Patients Enrolled	Unresectable locally advanced or metastatic recurrent or relapsing disease.
Administration Dosage	Mesothelin-positive patients with selected adenocarcinomas (NSCLC, triple negative breast, gastric including gastroesophageal junction) and thymic carcinoma will receive anetumab ravtansine as monotherapy at 6.50 mg/kg IV on a 21-day cycle. Patients with cholangiocarcinoma will receive anetumab ravtansine in combination with cisplatin (25 mg/m2 IV day 1 and 8 on a 21-day cycle for up to 6 cycles) and patients with pancreatic adenocarcinoma will receive anetumab ravtansine in combination with gemcitabine (1000 mg/m2 IV day 1 and 8 on a 21-day cycle).    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT03102320	Clinical Status	Phase 1
Clinical Description	Phase 1b multi-indication study of anetumab ravtansine (BAY94-9343) in patients with mesothelin expressing advanced or recurrent malignancies.
Experiment 13 Reporting the Activity Date of This ADC					[25]
Related Clinical Trial
NCT Number	NCT02824042	Clinical Status	Phase 1
Clinical Description	An open label, phase 1 study to assess the effect of itraconazole (CYP3A4 and P-gp Inhibitor) on the pharmacokinetics of anetumab ravtansine and to assess the ECG Effects, safety and immunogenicity of anetumab ravtansine given as a single agent and together with itraconazole in subjects with mesothelin-expressing advanced solid cancers.
Experiment 14 Reporting the Activity Date of This ADC					[26]
Related Clinical Trial
NCT Number	NCT02751918	Clinical Status	Phase 1
Clinical Description	An open-label phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and maximum tolerated dose of anetumab ravtansine in combination with pegylated liposomal doxorubicin 30 mg/m<sup>2</sup> given every 3 weeks in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer.    Click to Show/Hide
Experiment 15 Reporting the Activity Date of This ADC					[27]
Related Clinical Trial
NCT Number	NCT02696642	Clinical Status	Phase 1
Clinical Description	An open label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with mesothelin-expressing advanced solid cancers and different stages of concurrent hepatic or renal impairment.
Experiment 16 Reporting the Activity Date of This ADC					[28]
Related Clinical Trial
NCT Number	NCT02639091	Clinical Status	Phase 1
Clinical Description	An open label phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and maximum tolerated dose of anetumab ravtansine in combination with pemetrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup> in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.    Click to Show/Hide
Experiment 17 Reporting the Activity Date of This ADC					[29]
Related Clinical Trial
NCT Number	NCT02485119	Clinical Status	Phase 1
Clinical Description	An open label, phase 1 study to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given by intravenous infusion every 3 weeks (Q3W) in Japanese subjects with advanced malignancies.

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	0.00% (Day 70)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing cervical squamous cell carcinoma PDX model (PDX: Caski)
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	0.00% (Day 70)	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: Cx-03)
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00% (Day 27)	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: T1889)
Experiment 4 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.70% (Day 153)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.03 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing mesothelioma PDX model (PDX: NCI-H226)
Experiment 5 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	25.00% (Day 70)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: Cx-03)
Experiment 6 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	27.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing serous papillary carcinoma PDX model (PDX: ST206B)
Experiment 7 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 35.10% (Day 28)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3x106 MIA PaCa-2/vector,3x106 MIA PaCa-2/meso, 1x106 HT-29/vector, 1x106 HT-29/meso ,3x106 OVCAR-3, or 3x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.01 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing pancreatic carcinoma PDX model (PDX: MIA PaCa-2/meso)
Experiment 8 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	42.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: OVCAR-8)
Experiment 9 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	42.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: OVCAR-8)
Experiment 10 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	49.00%	Moderate MSLN expression (MSLN++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: ST081)
Experiment 11 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.50% (Day 27)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: T1889)
Experiment 12 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	54.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: OVCAR-8)
Experiment 13 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	57.10% (Day 70)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: Cx-03)
Experiment 14 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.10% (Day 27)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: T1889)
Experiment 15 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	64.00%	Moderate MSLN expression (MSLN++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous papillary carcinoma PDX model (PDX: ST409)
Experiment 16 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	64.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: Ov6668)
Experiment 17 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 64.30% (Day 21)	Low Mesothelin expression (MSLN+; IHC 1+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing colon carcinoma model PDX model (PDX: HT-29/meso)
Experiment 18 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	65.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: OVCAR-8)
Experiment 19 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.70% (Day 153)	Low Mesothelin expression (MSLN+; IHC 1+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.03 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing mesothelioma PDX model (PDX: NCI-H226)
Experiment 20 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	73.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: Ov6668)
Experiment 21 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	74.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: ST081)
Experiment 22 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	75.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing serous papillary carcinoma PDX model (PDX: ST467)
Experiment 23 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	83.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: OVCAR-3)
Experiment 24 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	83.00%	Negative Mesothelin expression (MSLN-)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: Ov6668)
Experiment 25 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.30% (Day 90)	Low Mesothelin expression (MSLN+; IHC 1+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3x106 MIA PaCa-2/vector, 3x106 MIA PaCa-2/meso,1x106 HT-29/vector, 1x106 HT-29/meso, 3x106 OVCAR-3, or 3x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. BAY 94-9343 administered at 0.05 mg/kg, 0.2 mg/kg (corresponding to 14.3 mg/kg ADC; Q3Dx3).    Click to Show/Hide
In Vivo Model	Ovarian cancer PDX model (PDX: OVCAR6719)
Experiment 26 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.90% (Day 27)	Low Mesothelin expression (MSLN+; IHC 1+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: T1889)
Experiment 27 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85.00%	Negative Mesothelin expression (MSLN-)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: ST081)
Experiment 28 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.00% (Day 60)	Low Mesothelin expression (MSLN+; IHC 1+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3x106 MIA PaCa-2/vector, 3x106 MIA PaCa-2/meso,1x106 HT-29/vector, 1x106 HT-29/meso, 3x106 OVCAR-3, or 3x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. BAY 94-9343 administered at 0.05 mg/kg, 0.2 mg/kg (corresponding to 14.3 mg/kg ADC; Q3Dx3).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing pancreatic tumor PDX model (PDX: PAXF736)
Experiment 29 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90.00%	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: OVCAR-3)
Experiment 30 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.40% (Day 61)	Low MSLN expresion (MSLN+; 900 MSLN molecules/cell)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: OVCAR-36)
Experiment 31 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.60% (Day 153)	High MSLN expresion (MSLN+++; 41,887 MSLN molecules/cell)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.03 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing mesothelioma PDX model (PDX: NCI-H226)
Experiment 32 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.20% (Day 61)	Moderate MSLN expresion (MSLN++; 1,260 MSLN molecules/cell)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g,7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.01 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: OVCAR-36)
Experiment 33 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.70% (Day 27)	High MSLN expresion (MSLN+++; 53,497 MSLN molecules/cell)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing uterine carcinosarcoma PDX model (PDX: T1889)
Experiment 34 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	96.00%	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous papillary carcinoma PDX model (PDX: ST270)
Experiment 35 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	96.00%	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing ovarian cancer PDX model (PDX: OVCAR-3)
Experiment 36 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 20)	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.01 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing pancreatic carcinoma PDX model (PDX: MIA PaCa-2/meso)
Experiment 37 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 20)	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.01 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing pancreatic carcinoma PDX model (PDX: MIA PaCa-2/meso)
Experiment 38 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 21)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. 0.01 mg/kg , 0.05 mg/kg , 0.2 mg/kg Anetumab ravtansine was i.v. to the tumor-bearing mice.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing colon carcinoma model PDX model (PDX: HT-29/meso)
Experiment 39 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 90)	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. BAY 94-9343 administered at 0.05 mg/kg,0.2 mg/kg (corresponding to 14.3 mg/kg ADC; Q3Dx3).    Click to Show/Hide
In Vivo Model	Ovarian cancer PDX model (PDX: OVCAR6719)
Experiment 40 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 90)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. BAY 94-9343 administered at 0.05 mg/kg,0.2 mg/kg (corresponding to 14.3 mg/kg ADC; Q3Dx3).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing mesothelioma model PDX model (PDX: Meso7212)
Experiment 41 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 90)	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	For subcutaneous tumor models,female NMRI nu/nu mice (18-25 g, 7-10 weeks) from Taconic M&B were implanted on day 0 with either 3 x106 MIA PaCa-2/vector,3 x106 MIA PaCa-2/meso,1 x106 HT-29/vector,1 x106 HT-29/meso,3 x106 OVCAR-3,or 3 x106 NCI-H226 cells suspended in 0.1 mL 50% Matrigel. Patient-derived pancreatic (PAXF736) model was performed at Oncotest GmbH and ovarian (OVCAR6719) and mesothelioma (Meso7212) models at EPO Berlin-Buch GmbH. BAY 94-9343 administered at 0.05 mg/kg,0.2 mg/kg (corresponding to 14.3 mg/kg ADC; Q3Dx3).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing mesothelioma model PDX model (PDX: Meso7212)
Experiment 42 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Moderate Mesothelin expression (MSLN++; IHC 2+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade serous ovarian cancer PDX model (PDX: ST081)
Experiment 43 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	High Mesothelin expression (MSLN+++; IHC 3+)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive ovarian cancer cell line- and patient-derived xenograft models. For the OVCAR-3 and OVCAR-8 xenograft models,tumor cells in Matrigel were inoculated subcutaneously to the right lower flank region of female nude/nude mice. In the monotherapy experiments,anetumab ravtansine was administered intravenously (i.v.) at 2.5 mg/kg three times every third day (Q3Dx3). For the in vivo combination studies with pegylated liposomal doxorubicin (PLD) or copanlisib in OVCAR-8 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,7,28,32 and 35,or on days 1,4,28 and 35,respectively. For the in vivo combination studies in OVCAR-3 xenografts,anetumab ravtansine was administered i.v. at 2.5 mg/kg on days 1,4,43 and 46. For the Ov6668 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg on day 1 and at 15 mg/kg on days 16,30,43,57 and 71. For the ST081 xenografts,anetumab ravtansine was administered i.v. at 3.75 mg/kg every second week (Q2W). PLD was administered i.v. at 4 mg/kg on days 1,7,28 and 35 (OVCAR-8 xenografts),on days 1 and 30 (Ov6668 xenografts) or on days 0 and 7 (ST081 xenografts). Carboplatin was administered i.v. at 80 mg/kg QWx2. Copanlisib was administered at 10 mg/kg,2 days on/5 days off,i.v.,starting on day 2. Bevacizumab was administered intraperitoneally (i.p.) at 0.3 mg/kg,every fifth day (Q5D).    Click to Show/Hide
In Vivo Model	Mesothelin-expressing high-grade ovarian cancer PDX model (PDX: ST103)

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	25.00% (Day 70)	High MSLN expression (MSLN+++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Four groups of mice,each consisting of 58 animals was set up and vital Hela cells were inoculated in a dose of 110e5 cells in 100 l by subcutaneous injection in the left inner flank on day 0. Animals in the treatment groups received 2 mg/kg,5 mg/kg,and 10 mg/kg anetumab ravtansine in 200 l injection buffer twice weekly by i.p. injection. Animals in the control group received injection buffer only.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	25.00% (Day 70)	High MSLN expression (MSLN+++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing cervical squamous cell carcinoma hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 3 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	50.00% (Day 70)	High MSLN expression (MSLN+++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing cervical squamous cell carcinoma hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	75.00% (Day 70)	Negative MSLN expression (MSLN-)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Four groups of mice,each consisting of 58 animals was set up and vital Hela cells were inoculated in a dose of 110e5 cells in 100 l by subcutaneous injection in the left inner flank on day 0. Animals in the treatment groups received 2 mg/kg,5 mg/kg,and 10 mg/kg anetumab ravtansine in 200 l injection buffer twice weekly by i.p. injection. Animals in the control group received injection buffer only.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 5 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85.70% (Day 70)	Moderate MSLN expression (MSLN++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Mice were subcutaneously inoculated with 5x106 MSLN positive T1889 cells mixed with Matrigel. Treatment then began, and the experiments ran for a total of 4 weeks. The first treatment cohort of 32 mice consisted of vehicle control, isotype ADC control, and 15 mg/kg ARav, dosed at Q7D via intraperitoneal injection. A second treatment cohort of 30 mice occurred with groups consisting of vehicle control (Q14D), 7.5 mg/kg ARav (Q14D) monotherapy, 7.5 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy. A third treatment cohort of 32 mice occurred with groups consisting of vehicle control (Q14D), 3.75 mg/kg ARav (Q14D) monotherapy, 3.75 mg/kg ARav (Q14D) and 4 mg/kg cisplatin (Q7D) combination therapy, and 4 mg/kg cisplatin (Q7D) monotherapy.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing cervical squamous cell carcinoma hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 6 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88.00% (Day 70)	Positive Mesothelin expression (MSLN+++/++)
Method Description	The in vivo antitumor activity of Anetumab ravtansine was evaluated in a Mesothelin positive xenograft tumor models. Four groups of mice,each consisting of 58 animals was set up and vital Hela cells were inoculated in a dose of 110e5 cells in 100 l by subcutaneous injection in the left inner flank on day 0. Animals in the treatment groups received 2 mg/kg,5 mg/kg,and 10 mg/kg anetumab ravtansine in 200 l injection buffer twice weekly by i.p. injection. Animals in the control group received injection buffer only.    Click to Show/Hide
In Vivo Model	Mesothelin-expressing hela CDX model
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.05 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 3 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.59 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells (MSLN expression)		CVCL_0428
Experiment 4 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.59 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 5 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.10 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 6 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.72 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 7 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.90 nM	Low MSLN expresion (MSLN+; 952 MSLN molecules/cell)
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian adenocarcinoma	BG1 cells		CVCL_6570
Experiment 8 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.15 nM
Method Description	The inhibitory activity of BAY 94-9343 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Colon adenocarcinoma	HT-29 cells (MSLN expression)		CVCL_0320
Experiment 9 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.90 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 10 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.90 nM	Moderate MSLN expresion (MSLN++; 3,875 MSLN molecules/cell)
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-5 cells		CVCL_1628
Experiment 11 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.40 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313
Experiment 12 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.70 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian endometrioid adenocarcinoma	A2780 cells		CVCL_0134
Experiment 13 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.80 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous cystadenocarcinoma	EFO-21 cells		CVCL_0029
Experiment 14 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	32.50 nM	Moderate MSLN expresion (MSLN++; 9,648 MSLN molecules/cell)
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	High grade ovarian serous adenocarcinoma	OVCAR-8 cells		CVCL_1629
Experiment 15 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.90 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 16 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	42.40 nM
Method Description	The inhibitory activity of anetumab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	High grade ovarian serous adenocarcinoma	NCI-ADR-RES cells		CVCL_1452

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Objective Response Rate (ORR)	3.20% (on the single-dose regimen) 5.90% (the multi-dose regimen)
Patients Enrolled	Relapsed and/or refractory multiple myeloma (MM) previously treated with an immunomodulatory drug and a proteasome inhibitor.
Administration Dosage	In the first-in-human study, indatuximab ravtansine (10, 20, 40, 80, 120, 160, 200 mg/m2) was administered to 32 patients on day 1 of each 21-day cycle. The MTD was 160 mg/m2. In the phase I/IIa study, indatuximab ravtansine (40, 50, 65, 80, 100, 120, 140, 160 mg/m2) was administered to 35 patients on days 1, 8, and 15 of each 28-day cycle, and the MTD/recommended phase II dose was 140 mg/m2.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT00723359	Clinical Status	Phase 1
Clinical Description	A phase 1 dose escalation study to evaluate maximum tolerated dose (MTD), pharmacokinetics (PK), and safety of BT062 in subjects with relapsed or relapsed/refractory multiple myeloma.
Primary Endpoint	The 160 mg/m2 dose was therefore defined as MTD for the Single-dose Regimen.
Other Endpoint	Most (88.00%) adverse events were grade 1 or 2, the most common being diarrhea and fatigue. There was rapid clearance of indatuximab ravtansine and no relevant accumulation.
Experiment 2 Reporting the Activity Date of This ADC					[30]
Patients Enrolled	Relapsed or refractory multiple myeloma, and ECOG performance status or Zubrod score of 2 or below.
Administration Dosage	Intravenously on days 1, 8, and 15 of each 28-day cycle in escalating dose levels of 80 mg/m2, 100 mg/m2, and 120 mg/m2, with lenalidomide (25 mg; days 1 to 21 every 28 days orally) and dexamethasone (20-40 mg; days 1, 8, 15, and 22 every 28 days) (phase 1).
Related Clinical Trial
NCT Number	NCT01638936	Clinical Status	Phase 1
Clinical Description	A phase 1/2a multi-dose escalation study of BT062 in combination with lenalidomide or pomalidomide and dexamethasone in subjects with relapsed or relapsed/refractory multiple myeloma.

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00% (Day 39)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 1 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF1384)
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00%	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 2 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF1384)
Experiment 3 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00% (Day 39)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 4 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF1384)
Experiment 4 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 25.00% (Day 38)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 1 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF401)
Experiment 5 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.00% (Day 38)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 2 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF401)
Experiment 6 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.00% (Day 39)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine combination docetaxel against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated docetaxel with 10 mg/kg and treated indatuximab ravtansine with 2 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF1384)
Experiment 7 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70.00% (Day 39)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 8mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF1384)
Experiment 8 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.50% (Day 38)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 4 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF401)
Experiment 9 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.80% (Day 38)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 8mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF401)
Experiment 10 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 38)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine combination docetaxel against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated docetaxel with 10 mg/kg and treated indatuximab ravtansine with 2 mg/kg.
In Vivo Model	Triple-negative breast cancer PDX model (PDX: MAXF401)

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.86% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine combination lenalidomide against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 5.3 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.42% (Day 17)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 2 mg/kg/day.
In Vitro Model	Plasma cell myeloma	MMXF L363 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.00% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 5.3 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.69% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine combination lenalidomide against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 10.6 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.90% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 10.6 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65.34% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 21.2 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 77.26% (Day 17)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 4 mg/kg/day.
In Vitro Model	Plasma cell myeloma	MMXF L363 cells		Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 77.27% (Day 17)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine+lenalidomide (Len; 20 mg/kg/day) and dexamethasone (1.25 mg/kg/day) against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated IR with 2 mg/kg/day.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 9 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.20% (Day 14)	Moderate CD138 expression (CD138++)
Method Description	The inhibitory activity of indatuximab ravtansine combination lenalidomide against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 21.2 mg/kg body weight for 14 days.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens
Experiment 10 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.05% (Day 17)	High CD138 expression (CD138+++)
Method Description	The inhibitory activity of indatuximab ravtansine+lenalidomide (Len; 20 mg/kg/day) and dexamethasone (1.25 mg/kg/day) against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated IR with 4 mg/kg/day.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[38]
Related Clinical Trial
NCT Number	NCT04064359	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label, dose finding study to assess the safety, tolerability, PK, and preliminary efficacy of OBT076, a CD205-directed ADC, in recurrent and/or metastatic CD205+ solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[38]
Related Clinical Trial
NCT Number	NCT03403725	Clinical Status	Phase 1
Clinical Description	Open-label, multicenter, phase 1 dose escalation study of MEN1309, a CD205 antibody-drug conjugate,in patients with CD205-positive metastatic solid tumors and non-Hodgkin lymphoma.

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.00% (Day 42)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: AspC1)
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 11.20% (Day 42)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: AspC1)
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 14.50% (Day 42)	Negative CD205 expression (CD205-; IHC 0)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: AspC1)
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.50% (Day 42)	Negative CD205 expression (CD205-; IHC 0)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: AspC1)
Experiment 5 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20.50% (Day 33)	Negative CD205 expression (CD205-; IHC 0)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: HPAFII)
Experiment 6 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.80% (Day 50)	Negative CD205 expression (CD205-; IHC 0)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer PDX model (PDX: PDX-22)
Experiment 7 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.70% (Day 18)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Bladder cancer PDX model (PDX: PDX-CTG-1652)
Experiment 8 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.30% (Day 18)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Bladder cancer PDX model (PDX: PDX-CTG-1388)
Experiment 9 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.00% (Day 57)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: PDX-21)
Experiment 10 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.20% (Day 33)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: HPAFII)
Experiment 11 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70.60% (Day 110)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-P6P)
Experiment 12 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.60% (Day 33)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: HPAFII)
Experiment 13 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.40% (Day 56)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer PDX model (PDX: PDX-347)
Experiment 14 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.90% (Day 33)	High CD205 expression (CD205+++; IHC 3+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,10 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: HPAFII)

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 22.70% (Day 50)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC70 CDX model
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.60% (Day 40)	Moderate CD205 expression (CD205++)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Urinary bladder cancer SW780 model
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.70% (Day 40)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC1806 CDX model
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.30% (Day 40)	High CD205 expression (CD205+++)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Urinary bladder cancer SW780 model
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728
Experiment 5 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 74.00% (Day 25)	Low CD205 expression (CD205+; IHC 1+)
Method Description	The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously with a single dose, 5 mg/kg.    Click to Show/Hide
In Vivo Model	Pancreas cancer CDX model
In Vitro Model	Pancreatic cancer	Pancreatic cancer cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.90% (Day 40)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC1806 CDX model
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 7 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.00% (Day 40)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC1806 CDX model
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 8 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.50% (Day 40)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Urinary bladder cancer SW780 model
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728
Experiment 9 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.80% (Day 50)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC70 CDX model
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 10 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.20% (Day 50)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC70 CDX model
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 11 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.50% (Day 25)	Low CD205 expression (CD205+; IHC 1+)
Method Description	The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously once weekly for 2 consecutive weeks, 5 mg/kg.    Click to Show/Hide
In Vivo Model	Diffuse Large B-Cell Lymphoma CDX model
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 12 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.60% (Day 40)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC1806 CDX model
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 13 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.70% (Day 50)	Low CD205 expression (CD205+; IHC 1+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer HCC70 CDX model
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 14 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.80% (Day 40)	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,10 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.    Click to Show/Hide
In Vivo Model	Urinary bladder cancer SW780 model
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	100.00 pM	High CD205 expression (CD205+++; IHC 3+)
Method Description	The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
In Vitro Model	Mantle cell lymphoma	Mantle cell lymphoma cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	110.00 pM	High CD205 expression (CD205+++; IHC 3+)
Method Description	The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
In Vitro Model	Marginal zone lymphoma	Marginal zone lymphoma cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	200.00 pM	High CD205 expression (CD205+++; IHC 3+)
Method Description	The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
In Vitro Model	Diffuse large B-cell lymphoma	Diffuse large B-cell lymphoma cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300.00 pM	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313
Experiment 5 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	310.00 pM	Low CD205 expression (CD205+; IHC 1+)
Method Description	The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
In Vitro Model	B-cell chronic lymphocytic leukemia	PCL12 cells		CVCL_2H32
Experiment 6 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.10 nM	High CD205 expression (CD205+++; IHC 3+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Pancreatic ductal adenocarcinoma	HPAF-II cells		CVCL_0313
Experiment 7 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.26 nM	Low CD205 expression (CD205+; IHC 1+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Bladder carcinoma	SW780 cells		CVCL_1728
Experiment 8 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.37 nM
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 9 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.40 nM	Negative CD205 expression (CD205-; IHC 0)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 10 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.43 nM	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 11 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.71 nM	Moderate CD205 expression (CD205++; IHC 2+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 12 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 nM	Negative CD205 expression (CD205-; IHC 0)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 13 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.82 nM
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 14 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.32 nM	Low CD205 expression (CD205+; IHC 1+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Pancreatic adenocarcinoma	SU.86.86 cells		CVCL_3881
Experiment 15 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.20 nM
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 16 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	22.66 nM	Negative CD205 expression (CD205-; IHC 0)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 17 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Effective Concentration (EC50)	36.23 nM	High CD205 expression (CD205+++; IHC 3+)
Method Description	The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
In Vitro Model	Recurrent bladder carcinoma	HT-1197 cells		CVCL_1291

Experiment 1 Reporting the Activity Date of This ADC					[39]
Related Clinical Trial
NCT Number	NCT00674947	Clinical Status	Phase 1
Clinical Description	A phase 1 study of B2B015, a humanized, IgG1, DM4-conjugated, anti-cripto, monoclonal antibody, for the treatment of subjects with relapsed or refractory solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.40% (Day 33)	High TDGF1 expression (TDGF1+++)
Method Description	NCCIT cells were inoculated into 8-week old male athymic nude mice. MDA-MB-231 cells were inoculated into 7-week old female CB17 SCID mice. Calu-6,human non-small cell lung cancer cells (ATCC) were maintained in MEM Earless BSS/NEAA/10%FBS media without antibiotics and inoculated subcutaneously (SC) into the right flank of 9-week old female athymic nude mice. For the CT-3 tumour model,primary human colon tumour tissue was serially transplanted in vivo to establish a SC xenograft model. Cryopreserved tumour fragments were thawed and serially passaged SC in female SCID beige mice at 810 weeks old for two to five generations prior to implantation for studies.    Click to Show/Hide
In Vivo Model	MDA-MB-231 xenograft model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.60% (Day 56)	Positive CD138 expression (CD138+++/++)
Method Description	Bispecific nBT062-natalizumab-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model	Breast cancer PDX model (PDX: MAXF 1322)

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Positive CD138 expression (CD138+++/++)
Method Description	WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.42% (Day 50)	Positive DOG1 expression (DOG1 +++/++)
Method Description	5 mg/kg anti-DOG1 ADC and control (PBS) were administered Q3Dx3 via tail vein injection to mice once every three days for a total of three doses.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.90% (Day 50)	Positive DOG1 expression (DOG1 +++/++)
Method Description	10 mg/kg anti-DOG1 ADC and control (PBS) were administered Q3Dx3 via tail vein injection to mice once every three days for a total of three doses.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.69% (Day 17)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 5 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	Kyse-410 CDX model
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-410 cells		CVCL_1352
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.30% (Day 25)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 5 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	HepG2 CDX model
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.32% (Day 25)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 5 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 4 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.04% (Day 25)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 10 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	HepG2 CDX model
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 5 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.11% (Day 21)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 5 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	MGC-803 CDX model
In Vitro Model	Gastric cancer	MGC-803 cells		CVCL_5334
Experiment 6 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.53% (Day 17)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 10 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	Kyse-410 CDX model
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-410 cells		CVCL_1352
Experiment 7 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.24% (Day 21)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 10 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	MGC-803 CDX model
In Vitro Model	Gastric cancer	MGC-803 cells		CVCL_5334
Experiment 8 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.67% (Day 25)	Positive DOG1 expression (DOG1 +++/++)
Method Description	Nude mice were used to establish cell line derived xenograft (CDX) models. After tumor inoculation, the tumor bearing mice were intravenously injected with naked anti-DOG1 antibody or a 10 mg/kg Q3Dx3 dose of the anti-DOG1 ADC.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.37 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Gastrointestinal stromal tumor	GIST882 cells		CVCL_7044
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.87 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Gastrointestinal stromal tumor	GIST882 cells (Imatinib resistant)		CVCL_7044
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.91 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 4 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12.11 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-410 cells		CVCL_1352
Experiment 5 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.92 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Gastric cancer	MGC-803 cells		CVCL_5334
Experiment 6 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.56 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 7 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	33.19 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Adult hepatocellular carcinoma	HCCLM3 cells		CVCL_6832
Experiment 8 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39.99 nM	Positive DOG1 expression (DOG1 +++/++)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 9 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 200 nM	Negative DOG1 expression (DOG1 -)
Method Description	Cancer cells were treated with anti-DOG1-DM4-ADC or naked anti-DOG1 antibody (as control) at different concentrations for 72 hours.Viable cell counts were determined with RTCA assays and the IC 50 values were calculated.
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 56)	Positive CD138 expression (CD138+++/++)
Method Description	Stable nBT062-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model	Breast cancer PDX model (PDX: MAXF 1322)

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM±0.01 nM	Positive CD138 expression (CD138+++/++)
Method Description	WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 56)	Positive CD138 expression (CD138+++/++)
Method Description	Half nBT062-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model	Breast cancer PDX model (PDX: MAXF 1322)

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.085 nM±0.005 nM	Positive CD138 expression (CD138+++/++)
Method Description	WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 56)	Positive CD138 expression (CD138+++/++)
Method Description	Wild type nBT062-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model	Breast cancer PDX model (PDX: MAXF 1322)

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM±0.02 nM	Positive CD138 expression (CD138+++/++)
Method Description	WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 13.34% (Day 36)	High HER2 expression (HER2+++)
Method Description	The inhibitory activity of trastuzumab-gelonin against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 2.5 mg/kg.
In Vivo Model	Gastric cancer CDX model
In Vitro Model	Gastric cancer	Gastric cancer cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.57% (Day 36)	High HER2 expression (HER2+++)
Method Description	The inhibitory activity of trastuzumab-gelonin+LE8 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 2.5 mg/kg.
In Vivo Model	Gastric cancer CDX model
In Vitro Model	Gastric cancer	Gastric cancer cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.79% (Day 36)	High HER2 expression (HER2+++)
Method Description	The inhibitory activity of trastuzumab-gelonin+1HE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 2.5 mg/kg.
In Vivo Model	Gastric cancer CDX model
In Vitro Model	Gastric cancer	Gastric cancer cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.22±0.08 nM	High HER2 expression (HER2+++)
Method Description	The inhibitory activity of trastuzumab-gelonin against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	555.00±69.60 nM	High HER2 expression (HER2+++)
Method Description	The inhibitory activity of unconjugated rGel against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	30.00% (Day 20)	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 50 mg/kg, equivalent to 82 g conjugated maytansinoid per kg The conjugates were injected on day 4 after cell inoculation.
In Vivo Model	FRalpha-positive KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 31.88% (Day 14)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with Kasumi-1 cells. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of 2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (1 mg/kg).    Click to Show/Hide
In Vivo Model	Kasumi-1 CDX model
In Vitro Model	Myeloid leukemia with maturation	Kasumi-1 cells		CVCL_0589
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.94% (Day 35)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with Kasumi-1 cells. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of 2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (10 mg/kg).    Click to Show/Hide
In Vivo Model	HMC-1 CDX model
In Vitro Model	Mast cell leukemia	HMC-1 cells		CVCL_0003
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.00% (Day 50)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with 10,000,000 cells. The total injection volume containingcells in suspension was 200 ul. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (2.5 mg/kg).    Click to Show/Hide
In Vivo Model	GIST-T1 CDX model
In Vitro Model	Gastrointestinal stromal tumor	GIST-T1 cells		CVCL_4976
Experiment 4 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.00% (Day 43)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with 10,000,000 cells. The total injection volume containingcells in suspension was 200 ul. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (5 mg/kg).    Click to Show/Hide
In Vivo Model	GIST430 CDX model
In Vitro Model	Gastrointestinal stromal tumor	GIST430 cells		CVCL_7040
Experiment 5 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.09% (Day 14)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with Kasumi-1 cells. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of 2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (5 mg/kg).    Click to Show/Hide
In Vivo Model	Kasumi-1 CDX model
In Vitro Model	Myeloid leukemia with maturation	Kasumi-1 cells		CVCL_0589
Experiment 6 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 50)	Positive KIT expression (KIT+++/++)
Method Description	Female SCID-beige mice were implanted subcutaneously with 10,000,000 cells. The total injection volume containingcells in suspension was 200 ul. Mice were enrolled in the study 15 days post implantation withaverage tumor volume of about 120 mm3. All treated groups received a single intravenous dose of2 mg/kg. After being randomly assigned to groups (n = 8/group), mice were administered a single i.v.dose of TBS (5 ml/kg) or ADC (5 mg/kg).    Click to Show/Hide
In Vivo Model	GIST-T1 CDX model
In Vitro Model	Gastrointestinal stromal tumor	GIST-T1 cells		CVCL_4976

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	65.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Gastrointestinal stromal tumor	GIST430 cells		CVCL_7040
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	75.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Gastrointestinal stromal tumor	GIST-T1 cells		CVCL_4976
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	84.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H889 cells		CVCL_1598
Experiment 4 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	88.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H1930 cells		CVCL_1507
Experiment 5 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	92.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 6 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	94.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 7 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	94.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	Kasumi-6 cells		CVCL_0614
Experiment 8 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	98.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 9 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	99.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute megakaryoblastic leukemia	M-07e cells		CVCL_2106
Experiment 10 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	99.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 11 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	100.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Myeloid leukemia with maturation	Kasumi-1 cells		CVCL_0589
Experiment 12 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	100.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	OCI-M1 cells		CVCL_2149
Experiment 13 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	100.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Essential thrombocythemia	UKE-1 cells		CVCL_0104
Experiment 14 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Max inhibition rate (MIR)	100.00%	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H1048 cells		CVCL_1453
Experiment 15 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.05 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Gastrointestinal stromal tumor	GIST-T1 cells		CVCL_4976
Experiment 16 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.07 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 17 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.11 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute megakaryoblastic leukemia	M-07e cells		CVCL_2106
Experiment 18 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.13 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	OCI-M1 cells		CVCL_2149
Experiment 19 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.17 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Gastrointestinal stromal tumor	GIST430 cells		CVCL_7040
Experiment 20 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.17 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 21 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.30 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H1930 cells		CVCL_1507
Experiment 22 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.83 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Myeloid leukemia with maturation	Kasumi-1 cells		CVCL_0589
Experiment 23 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	0.91 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	Kasumi-6 cells		CVCL_0614
Experiment 24 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	1.26 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 25 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	1.47 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H889 cells		CVCL_1598
Experiment 26 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	1.60 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 27 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	2.77 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H1048 cells		CVCL_1453
Experiment 28 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximum Growth Inhibitory Concentration (GI50)	5.60 nM	Positive KIT expression (KIT+++/++)
Method Description	Cells were cultured in a tissue culture incubator at 37°C with 5% CO2 in culture medium. On the day of the assay, cells were washed twice with PBS, prior to being treated with 0.1% trypsin-EDTA for 5 min and resuspended in the recommended culture medium. Cells were then counted and seeded in 96 well plates at densities of 2,000-10,000 cells/well in 100 ul of cell culture medium.    Click to Show/Hide
In Vitro Model	Essential thrombocythemia	UKE-1 cells		CVCL_0104

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian cancer	Ovarian cancer cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian cancer	Ovarian cancer cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.56% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 100g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124
Experiment 2 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.92% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 250g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124
Experiment 3 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.00% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 450g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	83.00% (Day 32)	High FOLR1 expression (FOLR1+++; 1,300,000 FOLR1 molecules/cell)
Method Description	Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 2.5±0.2 mg/kg, equivalent to 51±3 ug conjugated maytansinoid per kg The conjugates were injected on day 7 after cell inoculation.
In Vivo Model	Ovarian carcinoma Igrov-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.22% (Day 26)	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 2.5±0.2 mg/kg, equivalent to 51±3 ug conjugated maytansinoid per kg The conjugates were injected on day 20 after cell inoculation.
In Vivo Model	FRalpha-positive KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07±0.02 nM	High FOLR1 expression (FOLR1+++; 1,300,000 FOLR1 molecules/cell)
Method Description	Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08±0.01 nM	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.    Click to Show/Hide
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11±0.08 nM	Moderate FOLR1 expression (FOLR1++; 290,000 FOLR1 molecules/cell)
Method Description	Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x103 cells per well The plates were incubated at 37°C, 6% CO2 for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit.    Click to Show/Hide
In Vitro Model	Gestational choriocarcinoma	JEG-3 cells		CVCL_0363

Experiment 1 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.72% (Day 30)	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Mice were randomized by body weight into treatment groups and reated either singly (SPDB conjugates) on day 3 post cell inoculation, or three times weekly on days 3, 10, and 17 post KB cell inoculation with 5 mg/kg of a conjugate.
In Vivo Model	KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.08% (Day 17)	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 6 post cell inoculation with 2.5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 3 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 17)	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 6 post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 4 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugate in various concentrations was added to FOLR1-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 5 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugate in various concentrations was added to FOLR1-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 6 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.20 nM	Moderate FOLR1 expression (FOLR1 ++)
Method Description	Conjugate in various concentrations was added to FOLR1-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Gestational choriocarcinoma	JEG-3 cells		CVCL_0363

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.40% (Day 20)	Positive CD138 expression (CD138 +++/++)
Method Description	MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 250 ug/kg.
In Vivo Model	MOLP-8 CDX model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM-1.00 nM	Positive CD138 expression (CD138 +++/++)
Method Description	CD138+ MOLP-8 cells were seeded in flat bottom plates at 3000 cells/well. CD138- BJAB control cells were seeded at 1000 cells/weli. The cells were treated with nBT062-SPDB-DM4nBT062-SPP-DM1 or nBT062-SMCC-DM1 at different concentrations for five days.
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative CD138 expression (CD138 -)
Method Description	CD138+ MOLP-8 cells were seeded in flat bottom plates at 3000 cells/well. CD138- BJAB control cells were seeded at 1000 cells/weli. The cells were treated with nBT062-SPDB-DM4nBT062-SPP-DM1 or nBT062-SMCC-DM1 at different concentrations for five days.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 20)	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	Conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of OVCAR-3 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 37)	Positive CA6 expression (CA6 +++/++)
Method Description	The in vivo activity of huDS6v1.01-DM4 was tested onthe HPAC pancreatic model.HPAC cells were inoculated on Day 0, and immunoconjugate treatments were given on day13 (20 ug/kg). PBS control animals were euthanized once tumor vol-umes exceeded 1000 mm3.
In Vivo Model	HPAC CDX model
In Vitro Model	Pancreatic adenocarcinoma	HPAC cells		CVCL_3517

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 10.00 nM	Positive CA6 expression (CA6 +++/++)
Method Description	In the MTT assay, cells were seeded in 96-well plates ata density of 1000-5000 cells/well. The cells were plated with serial dilutions of huDS6v1.01-DM4 immunoconjugate in 200 pl of culture media. The cells and antibody/conjugate mixtures were then incubated for 2-7 d, at which time cellviability was assessed by an MTT assay.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 35)	Positive FGFR2 expression (FGFR2+++/++)
Method Description	The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 233 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 5 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.    Click to Show/Hide
In Vivo Model	SNU-16 CDX model
In Vitro Model	Gastric adenocarcinoma	SNU-16 cells		CVCL_0076

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.80 nM	Positive FGFR2 expression (FGFR2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	SNU-16 cells		CVCL_0076

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive FGFR2 expression (FGFR2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	SNU-16 cells		CVCL_0076

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Positive FGFR2 expression (FGFR2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	SNU-16 cells		CVCL_0076

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.10 ug/mL	Positive VEGFR2 expression (VEGFR2 +++/++)
Method Description	The Cell Counting Kit-8 (CCK8) method was used to detect the effect of nanocapsules on cell viability. The cultured U87 and HA1800 cells were placed in a 96-well plate at a density of 5 x 103 cells/well. After 24 h of culture, PBS, 2-DG/aV-siCPT1C NC were added.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.24 ug/mL	Positive ITGAV expression (ITGAV +++/++)
Method Description	Cells were seeded into white 96-well tissue culture plates (5000 cells/well)in culture medium and incubated for 16 hrs. Serial dilutions of immunoconjugates were added toeach appropraite wells (0-20 ug/ml). Tissue culture plates were incubated at 37°C for 96 hrs.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.30 ug/mL	Positive ITGAV expression (ITGAV +++/++)
Method Description	Cells were seeded into white 96-well tissue culture plates (5000 cells/well)in culture medium and incubated for 16 hrs. Serial dilutions of immunoconjugates were added toeach appropraite wells (0-20 ug/ml). Tissue culture plates were incubated at 37°C for 96 hrs.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.21 mg/mL	Positive ITGAV expression (ITGAV +++/++)
Method Description	Cells were harvested, rinsedsuspended in serum free DMEM, and sequentially incubated for 60 minutes on ice with serialdiluted CNTO 95,CNTO 364, CNTO 365 and CNTO 366 and FITC-labeled anti-humanantibody (10 mg/ml).
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.27 mg/mL	Positive ITGAV expression (ITGAV +++/++)
Method Description	Cells were harvested, rinsedsuspended in serum free DMEM, and sequentially incubated for 60 minutes on ice with serialdiluted CNTO 95,CNTO 364, CNTO 365 and CNTO 366 and FITC-labeled anti-humanantibody (10 mg/ml).
In Vitro Model	Ovarian endometrioid adenocarcinoma	A2780 cells		CVCL_0134
Experiment 5 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.34 mg/mL	Positive ITGAV expression (ITGAV +++/++)
Method Description	Cells were harvested, rinsedsuspended in serum free DMEM, and sequentially incubated for 60 minutes on ice with serialdiluted CNTO 95,CNTO 364, CNTO 365 and CNTO 366 and FITC-labeled anti-humanantibody (10 mg/ml).
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023

Experiment 1 Reporting the Activity Date of This ADC					[56]
Related Clinical Trial
NCT Number	NCT00620607	Clinical Status	Phase 2
Clinical Description	A phase 2, open label, multiple center study of HUC242-DM4 given as an intravenous infusion once every three weeks to patients with metastatic gastric or gastroesophageal junction carcinomas.
Experiment 2 Reporting the Activity Date of This ADC					[59]
Related Clinical Trial
NCT Number	NCT00352131	Clinical Status	Phase 1
Clinical Description	A phase 1 study to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors.
Experiment 3 Reporting the Activity Date of This ADC					[60]
Patients Enrolled	Metastatic or inoperable colorectal, pancreatic, and other CanAg-expressing tumors who have failed standard therapy (about 95% of pts. had received = 4 prior chemotherapy regimens).
Administration Dosage	A single intravenous (IV) infusion once every three weeks, 18, 36, 60, 90, 126, 168, 223, and 297 mg/m2.
Related Clinical Trial
NCT Number	NCT00352131	Clinical Status	Phase 1
Clinical Description	A phase 1 study to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors.
Primary Endpoint	HuC242-DM4 was well tolerated at the 168 mg/m2 dose level. The MTD is not yet defined.
Other Endpoint	No clinically significant myelosuppression and no formation of antibody to humanized antibody (HAHA) or drug (HADA).

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 48.85% (Day 20)	Positive CD138 expression (CD138 +++/++)
Method Description	MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 250 ug/kg.
In Vivo Model	MOLP-8 CDX model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells		CVCL_2124

Experiment 1 Reporting the Activity Date of This ADC					[57]
Related Clinical Trial
NCT Number	NCT02984683	Clinical Status	Phase 1
Clinical Description	Open-label phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic triple negative breast cancer.
Experiment 2 Reporting the Activity Date of This ADC					[58]
Related Clinical Trial
NCT Number	NCT01156870	Clinical Status	Phase 1
Clinical Description	Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as a single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[61]
Related Clinical Trial
NCT Number	NCT02575781	Clinical Status	Phase 1
Clinical Description	A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.